LYBALVI Trademark

Trademark Overview

On Wednesday, June 26, 2019, a trademark application was filed for LYBALVI with the United States Patent and Trademark Office. The USPTO has given the LYBALVI trademark a serial number of 88489837. The federal status of this trademark filing is REGISTERED as of Tuesday, November 29, 2022. This trademark is owned by Alkermes Pharma Ireland Limited. The LYBALVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
lybalvi

General Information

Serial Number88489837
Word MarkLYBALVI
Filing DateWednesday, June 26, 2019
Status700 - REGISTERED
Status DateTuesday, November 29, 2022
Registration Number6913410
Registration DateTuesday, November 29, 2022
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 29, 2019

Trademark Statements

Description of MarkThe mark consists of the word "LYBALVI" in blue below a curved two-paneled ribbon design, the bottom portion of the ribbon being blue and the top portion being metallic copper.
Goods and ServicesPharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
Indication of Colors claimedThe color(s) blue and metallic copper is/are claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, July 6, 2019
Primary Code005
First Use Anywhere DateMonday, October 11, 2021
First Use In Commerce DateFriday, October 15, 2021

Trademark Owner History

Party NameAlkermes Pharma Ireland Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDublin 4
IE
Party NameAlkermes Pharma Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDublin 4
IE
Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin 4
IE

Trademark Events

Event DateEvent Description
Tuesday, November 29, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, November 29, 2022REGISTERED-PRINCIPAL REGISTER
Friday, October 28, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, October 27, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, October 17, 2022ASSIGNED TO EXAMINER
Tuesday, October 4, 2022STATEMENT OF USE PROCESSING COMPLETE
Friday, December 17, 2021USE AMENDMENT FILED
Friday, January 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 6, 2022SOU EXTENSION 4 GRANTED
Friday, December 17, 2021SOU EXTENSION 4 FILED
Tuesday, December 28, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 17, 2021TEAS EXTENSION RECEIVED
Friday, December 17, 2021TEAS STATEMENT OF USE RECEIVED
Wednesday, October 6, 2021ASSIGNED TO EXAMINER
Thursday, March 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 23, 2021SOU EXTENSION 3 GRANTED
Tuesday, March 23, 2021SOU EXTENSION 3 FILED
Tuesday, March 23, 2021TEAS EXTENSION RECEIVED
Saturday, October 31, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 29, 2020SOU EXTENSION 2 GRANTED
Thursday, October 29, 2020SOU EXTENSION 2 FILED
Thursday, October 29, 2020TEAS EXTENSION RECEIVED
Saturday, March 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 26, 2020SOU EXTENSION 1 GRANTED
Thursday, March 26, 2020SOU EXTENSION 1 FILED
Thursday, March 26, 2020TEAS EXTENSION RECEIVED
Tuesday, December 24, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 29, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 29, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 9, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 25, 2019ASSIGNED TO LIE
Thursday, September 19, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 18, 2019EXAMINER'S AMENDMENT ENTERED
Wednesday, September 18, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, September 18, 2019EXAMINERS AMENDMENT E-MAILED
Wednesday, September 18, 2019EXAMINERS AMENDMENT -WRITTEN
Tuesday, September 17, 2019ASSIGNED TO EXAMINER
Tuesday, July 9, 2019NOTICE OF DESIGN SEARCH CODE E-MAILED
Saturday, July 6, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, June 29, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

lybalvi treatment depression bipolar diseases disorder pharmaceutical preparations resistant gain dyslipidemia